Angiotensin II receptors: Impact for COVID-19 severity.
Angiotensin Receptor Antagonists
/ pharmacology
Angiotensin-Converting Enzyme 2
/ metabolism
Angiotensin-Converting Enzyme Inhibitors
/ pharmacology
Animals
COVID-19
/ physiopathology
Humans
Obesity
/ complications
Pneumonia, Viral
/ drug therapy
Receptors, Angiotensin
/ drug effects
Renin-Angiotensin System
/ drug effects
SARS-CoV-2
/ isolation & purification
Severity of Illness Index
COVID-19 Drug Treatment
ACE2
COVID-19
RAS
adipose tissue
obesity
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
12
06
2020
revised:
29
06
2020
accepted:
07
07
2020
pubmed:
10
7
2020
medline:
13
1
2021
entrez:
10
7
2020
Statut:
ppublish
Résumé
COVID-19 is an outbreak of viral pneumonia which became a global health crisis, and the risk of morbidity and mortality of people with obesity are higher. SARS-CoV-2, the pathogen of COVID-19, enters into cells through binding to the Angiotensin Converting Enzyme (ACE) homolog-2 (ACE2). ACE2 is a regulator of two contrary pathways in renin angiotensin system (RAS): ACE-Ang-II-AT1R axis and ACE2-Ang 1-7-Mas axis. Viral entry process eventuates in downregulation of ACE2 and subsequent activation of ACE-Ang-II-AT1R axis. ACE-Ang II-AT1R axis increases lipid storage, reduces white-to-beige fat conversion and plays role in obesity. Conversely, adipose tissue is an important source of angiotensin, and obesity results in increased systemic RAS. ACE-Ang-II-AT1R axis, which has proinflammatory, profibrotic, prothrombotic, and vasoconstrictive effects, is potential mechanism of more severe SARS-CoV-2 infection. The link between obesity and severe COVID-19 may be attributed to ACE2 consumption and subsequent ACE-Ang-II-AT1R axis activation. Therefore, patients with SARS-CoV-2 infection may benefit from therapeutic strategies that activate ACE2-Ang 1-7-Mas axis, such as Ang II receptor blockers (ARBs), ACE inhibitors (ACEIs), Mas receptor agonists and ACE2.
Identifiants
pubmed: 32645228
doi: 10.1111/dth.13989
pmc: PMC7361069
doi:
Substances chimiques
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Receptors, Angiotensin
0
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13989Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Cancer Chemother Pharmacol. 2006 May;57(5):559-68
pubmed: 16096787
Obesity (Silver Spring). 2012 Jan;20(1):48-56
pubmed: 21979391
Metabolism. 2020 Jul;108:154251
pubmed: 32353356
J Mol Cell Cardiol. 2014 Jan;66:167-76
pubmed: 24332999
Biol Sex Differ. 2019 Sep 4;10(1):45
pubmed: 31484552
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Circ J. 2013;77(2):301-8
pubmed: 23328447
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Shock. 2015 Apr;43(4):395-404
pubmed: 25768373
Clin Infect Dis. 2020 Jul 28;71(15):896-897
pubmed: 32271368
Nat Commun. 2014 May 06;5:3594
pubmed: 24800825
J Biol Chem. 2013 May 31;288(22):15520-31
pubmed: 23592774
J Travel Med. 2020 May 18;27(3):
pubmed: 32186711
Circ Res. 2020 May 8;126(10):1456-1474
pubmed: 32264791
Zhonghua Bing Li Xue Za Zhi. 2020 May 8;49(5):411-417
pubmed: 32172546
Compr Physiol. 2017 Sep 12;7(4):1137-1150
pubmed: 28915321
FASEB J. 2001 Dec;15(14):2727-9
pubmed: 11606482
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
J Clin Med. 2020 Jan 18;9(1):
pubmed: 31963731
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Am J Hypertens. 2009 Jul;22(7):784-91
pubmed: 19444223
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 17;43(0):E016
pubmed: 32062957
J Med Virol. 2020 Oct;92(10):1701-1702
pubmed: 32379346
Endocrinology. 1997 Apr;138(4):1512-9
pubmed: 9075710
J Invest Dermatol. 2021 Jan;141(1):206-209.e1
pubmed: 32454066
Obes Res. 2001 Aug;9(8):486-91
pubmed: 11500529
Intensive Care Med. 2020 Apr;46(4):586-590
pubmed: 32125455
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
Respir Med. 2020 Jul;168:105996
pubmed: 32364961
Diabetes Care. 2020 Jul;43(7):1392-1398
pubmed: 32409502
J Virol. 2011 May;85(9):4122-34
pubmed: 21325420
Obesity (Silver Spring). 2020 Jul;28(7):1187-1190
pubmed: 32339391
Horm Metab Res. 2020 May;52(5):257-263
pubmed: 32340044
Biochem J. 1997 Feb 15;322 ( Pt 1):235-9
pubmed: 9078267
Obesity (Silver Spring). 2007 Jul;15(7):1643-6
pubmed: 17636081
Int J Obes (Lond). 2007 Feb;31(2):382-4
pubmed: 16703000
Nat Genet. 2000 Sep;26(1):13
pubmed: 10973236
Dermatol Ther. 2020 Nov;33(6):e13989
pubmed: 32645228
Nature. 2005 Jul 7;436(7047):112-6
pubmed: 16001071
Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7809-14
pubmed: 18490652
Cell Rep. 2019 Apr 9;27(2):514-524.e5
pubmed: 30970254
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
Chron Respir Dis. 2008;5(4):233-42
pubmed: 19029235
J Clin Endocrinol Metab. 2012 Feb;97(2):E183-92
pubmed: 22162470
Pharmacol Res. 2015 Dec;102:138-57
pubmed: 26470648
Hypertension. 2002 Sep;40(3):329-34
pubmed: 12215475
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Jun 24;48(6):450-455
pubmed: 32120458
Obesity (Silver Spring). 2020 Aug;28(8):1371-1373
pubmed: 32397007
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Amino Acids. 2015 Apr;47(4):693-705
pubmed: 25534429
Diabetes. 2016 Jan;65(1):85-95
pubmed: 26224885
Am J Hypertens. 2010 Apr;23(4):425-31
pubmed: 20057360
Nat Med. 2005 Aug;11(8):875-9
pubmed: 16007097
Am J Physiol Heart Circ Physiol. 2016 Jan 15;310(2):H137-52
pubmed: 26475588
Lancet Respir Med. 2020 Apr;8(4):e21
pubmed: 32171062
Hypertension. 1992 Apr;19(4):339-44
pubmed: 1555865
Exp Biol Med (Maywood). 2017 Jan;242(1):8-21
pubmed: 27550926
Virus Res. 2008 Sep;136(1-2):8-15
pubmed: 18554741
Cell. 2020 May 14;181(4):905-913.e7
pubmed: 32333836
Eur J Intern Med. 2020 Jun;76:14-20
pubmed: 32336612
Circ Res. 2020 Jun 5;126(12):1671-1681
pubmed: 32302265
Hypertension. 2020 Jul;76(1):51-58
pubmed: 32348166